Engineering Conferences International

ECI Digital Archives
Cell Culture Engineering XV

Proceedings

Spring 5-10-2016

Changes in product quality – what is comparable
“enough” and what is “similar enough?”
David Robinson
Robinson Vaccines and Biologics

Follow this and additional works at: http://dc.engconfintl.org/cellculture_xv
Part of the Biomedical Engineering and Bioengineering Commons
Recommended Citation
1. FDA Guidance for Industry: “Comparability Protocols – Protein Drug Products and Biologics Products – Chemistry,
Manufacturing and Controls Information” September 2003; ICH Guidance Q5E: “Comparability of Biotechnological/Biological
Products Subject to Changes in Their Manufacturing Process” 2. FDA Guidance for Industry: “Scientific Considerations in
Demonstrating Biosimilarity to a Reference Product”, September 2012; CHMP: “Guideline on similar biologic medicinal products
containing monoclonal antibodies – non-clinical and clinical issues”; 30MAY2012

This Abstract is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Cell Culture
Engineering XV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

Conference: ECI Cell Culture Engineering
Session II: Impact of Process Conditions on Product Quality
Changes in product quality – what is comparable “enough” and what is “similar enough”
David K. Robinson, Robinson Vaccines and Biologics LLC, USA
Regulatory guidance documents clearly outline the requirements for demonstrating analytical
comparability to support process changes and analytical similarity to support the approval of
biosimilars. These include demonstration that process changes do not produce differences in
product characteristics that might lead to an adverse impact on the safety or efficacy of the
product1. For biosimilar products, a stepwise approach is required that starts with sponsors
demonstrating that the product characteristics of the proposed biosimilar are either highly similar
to that of the originator reference product or that any observed differences can be demonstrated
to not impact the ability to leverage (or “conserve”) the safety and efficacy profile previously
demonstrated by the originator2. Some product characteristics are however uniquely sensitive to
small changes in process conditions, including but not limited to isoform charge distribution and
glycan profiles. Moreover, as analytical methods continue to evolve, the ability to quantitatively
detect small changes in these characteristics continues to improve. As such, every
biotechnologist is faced with the question of what is comparable enough and/or what is similar
enough. The author will review twenty years of regulatory feedback on these questions and
discuss how regulatory agencies in the major markets have answered these same questions.
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